Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 13, 2019 06:30 ET | Source: Veru Inc.

Veru Reports Strong Fiscal 2019 First Quarter Financial Results

-- Drug Development Advancing: Successful TADFIN Clinical Trial with NDA Filing in 2019; Two Prostate Cancer Clinical Trials Enrolling -- -- Company to Host Investor Conference Call on Wednesday,...
February 12, 2019 08:00 ET | Source: Veru Inc.

Veru Announces Scientific Presentations for Novel Prostate Cancer Drug Candidates at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium

MIAMI, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and urology...
February 06, 2019 08:30 ET | Source: Veru Inc.

Veru to Report Fiscal 2019 First-Quarter Financial Results, Host Conference Call on February 13th

MIAMI, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and urology...
January 22, 2019 08:30 ET | Source: Veru Inc.

Veru Initiates Clinical Trial for Proprietary, Novel, First-in-Class Drug for Advanced Prostate Cancer

--Open-Label Phase 1b/2 Clinical Trial Results Expected by Year-End-- -- Drug Addresses Significant Unmet Medical Need -- MIAMI, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:...
January 15, 2019 08:00 ET | Source: Veru Inc.

Veru Announces Acceptance of Four Abstracts for Presentation at the Genitourinary Cancer Symposium in February 2019

MIAMI, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that four abstracts have been accepted for poster presentation...
January 14, 2019 08:00 ET | Source: Veru Inc.

Veru Announces Successful Bioavailability and Bioequivalence Clinical Trial for Tadalafil and Finasteride Combination Tablet for Benign Prostatic Hyperplasia

MIAMI, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that the clinical trial of the Company’s proprietary Tadalafil...
December 13, 2018 06:30 ET | Source: Veru Inc.

Veru Reports Strong Net Revenues and Gross Profit for Fiscal 2018 Fourth-Quarter

-- Advancing Multiple Drug Candidates, Two Drugs Currently in Clinical Trials, Company Transforming into Biopharmaceutical with Focus on Prostate Cancer, Successfully Completes Stock Offering, Awarded...
December 06, 2018 08:30 ET | Source: Veru Inc.

Veru to Report Fiscal Year 2018 Financial Results, Host Conference Call on December 13th

MIAMI, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company, today announced that on Thursday, December 13, 2018, the company will report...
December 03, 2018 08:30 ET | Source: Veru Inc.

Veru Announces First Patient Dosed in Bioequivalence Clinical Trial for Combination Tadalafil – Finasteride Tablet for Benign Prostatic Hyperplasia

-- Combination Tablet Treats BPH Symptoms; Shrinks Prostate and Prevents BPH Progression -- -- NDA Submission Target Mid 2019 -- MIAMI, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU),...
November 13, 2018 08:30 ET | Source: Veru Inc.

Veru Advances Novel, First-in-Class Oral Tubulin Inhibitor for Refractory Metastatic Prostate Cancer

-- Submits Investigational New Drug Application to FDA -- -- Open Label Phase 1b/2 Clinical Trial Expected to Begin before end of 2018 -- MIAMI, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Veru Inc....